Skip to main content
PatentCliff

Imbruvica Patent Protection

44 patents · Pharmacyclics LLC, AbbVie Inc.

Reviewed by PatentCliff Editorial Team · Updated
C
Patent Strength
63/100
44
Total Patents
2
Assignees
2027
Earliest Expiration
2039
Latest Expiration

Patent Details

Patent #TitleAssigneeExpiresStatus
8476284Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8497277Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8952015Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8703780Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8735403Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
7514444Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8957079Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
9181257Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8697711Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8754091Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCJun 28, 20271.0y left
8563563Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCOct 26, 20271.3y left
8008309Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCMay 13, 20281.9y left
11672803Orange Book listed patentPharmacyclics LLCJun 3, 20314.9y left
9125889Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
8999999Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
9801881Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
10004746Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
10016435Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
9801883Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
10478439Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
10751342Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
8754090Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
9814721Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
10653696Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20315.4y left
10961251Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
10106548Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
10752634Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
9713617Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
10294231Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
9725455Drug substance (composition of matter) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
10294232Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
10125140Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCDec 3, 20337.4y left
9540382Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCFeb 18, 20347.7y left
9296753Drug substance & product patent (incl. pediatric exclusivity extension)Pharmacyclics LLCApr 30, 20347.8y left
9795604Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCApr 24, 20358.8y left
10463668Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCApr 24, 20358.8y left
10695350Orange Book listed patent (incl. pediatric exclusivity extension)Pharmacyclics LLCApr 24, 20358.8y left
12551448Drug product (formulation / method-of-use) patentPharmacyclics LLCMar 3, 20369.7y left
12364698Drug product (formulation / method-of-use) patentPharmacyclics LLCApr 6, 20369.8y left
10010507Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCSep 3, 203610.2y left
10213386Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCSep 3, 203610.2y left
9655857Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCSep 3, 203610.2y left
10828259Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension)Pharmacyclics LLCSep 3, 203610.2y left
12201690Drug product (formulation / method-of-use) patentPharmacyclics LLCJun 14, 203913.0y left

Imbruvica is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Imbruvica is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.